(Q37956659)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Eribulin mesylate for the treatment of late-stage breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author

Jean-Sébastien Frénel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Carole Gourmelon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Mario Campone

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

17 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

2883-2890

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Determination of drug binding to microtubules in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Predictors of competing mortality in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.637490

Halichondrins - antitumor polyether macrolides from a marine sponge

21 January 2018

1 reference

20 August 2023

https://opencitations.net/index/coci/api/v1/citations/10.1351/PAC198658050701

Identifiers

DOI

10.1517/14656566.2011.637490

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22087618%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference